25.98
price up icon0.74%   0.19
after-market After Hours: 25.64 -0.34 -1.31%
loading
Beam Therapeutics Inc stock is traded at $25.98, with a volume of 1.99M. It is up +0.74% in the last 24 hours and up +15.72% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$25.79
Open:
$25.47
24h Volume:
1.99M
Relative Volume:
0.78
Market Cap:
$2.63B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-14.35
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-1.29%
1M Performance:
+15.72%
6M Performance:
+52.82%
1Y Performance:
+6.69%
1-Day Range:
Value
$25.29
$26.38
1-Week Range:
Value
$23.53
$28.48
52-Week Range:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
509
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
25.98 2.61B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.81 104.76B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.67 63.06B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
578.05 60.32B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
843.66 51.55B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.76 34.49B 398.11M -1.03B -868.57M -5.7032

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-25 Initiated Jefferies Buy
Mar-28-25 Upgrade BofA Securities Neutral → Buy
Mar-10-25 Upgrade Scotiabank Sector Perform → Sector Outperform
Jan-29-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-06-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Jul-23-24 Initiated H.C. Wainwright Buy
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
10:01 AM

What analyst consensus says on Beam Therapeutics Inc. stockWeekly Volume Report & Step-by-Step Swing Trade Plans - newser.com

10:01 AM
pulisher
04:44 AM

Technical analysis overview for Beam Therapeutics Inc. stockEntry Point & AI Driven Stock Reports - newser.com

04:44 AM
pulisher
Oct 17, 2025

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet - sharewise.com

Oct 17, 2025
pulisher
Oct 17, 2025

Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? - sharewise.com

Oct 17, 2025
pulisher
Oct 17, 2025

Why Beam Therapeutics Inc. stock is favored by pension fundsRate Hike & Growth Oriented Trading Recommendations - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Should you wait for a breakout in Beam Therapeutics Inc.Weekly Market Summary & Safe Capital Growth Tips - newser.com

Oct 17, 2025
pulisher
Oct 15, 2025

Visualizing Beam Therapeutics Inc. stock with heatmapsEarnings Miss & Expert Verified Movement Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Published on: 2025-10-15 09:56:45 - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

What the charts say about Beam Therapeutics Inc. todayMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Sickle Cell Disease Pipeline Insights Report 2025: DelveInsight Highlights Cutting-Edge Treatments and Clinical Progress - The Globe and Mail

Oct 13, 2025
pulisher
Oct 12, 2025

Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 12, 2025
pulisher
Oct 11, 2025

Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN

Oct 11, 2025
pulisher
Oct 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus

Oct 10, 2025
pulisher
Oct 09, 2025

Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech

Oct 08, 2025
pulisher
Oct 08, 2025

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga

Oct 08, 2025
pulisher
Oct 08, 2025

What Does Wall Street Think About Beam Therapeutics (BEAM)? - Insider Monkey

Oct 08, 2025
pulisher
Oct 08, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Oct 08, 2025
pulisher
Oct 07, 2025

14 Biotech Stocks with High Potential - Insider Monkey

Oct 07, 2025
pulisher
Oct 06, 2025

Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com

Oct 06, 2025

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Beam Therapeutics Inc Stock (BEAM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Bellon Christine
Chief Legal Officer
Oct 01 '25
Sale
24.53
373
9,150
116,921
Evans John M.
CEO
Oct 01 '25
Option Exercise
0.67
25,000
16,750
1,011,667
Evans John M.
CEO
Oct 02 '25
Option Exercise
0.67
25,000
16,750
1,011,667
Evans John M.
CEO
Oct 02 '25
Sale
24.63
25,000
615,668
986,667
Evans John M.
CEO
Oct 01 '25
Sale
24.51
25,000
612,655
986,667
$37.01
price up icon 1.84%
$87.57
price up icon 0.30%
$33.17
price up icon 1.28%
$105.14
price up icon 0.06%
biotechnology ONC
$316.42
price down icon 0.50%
$165.76
price up icon 1.57%
Cap:     |  Volume (24h):